{"anticipatedPostingDate":"2030-11","denomUnitsSelected":"Participants","description":"Serum samples will be collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be further tested in screening assay, and positive samples will be further characterized for antibody titers.","reportingStatus":"NOT_POSTED","timeFrame":"Up to approximately 407 weeks","title":"Titers of ADAs Against Belantamab Mafodotin","type":"SECONDARY"}